Back to results
US 2017/0320963 A1Published application
Genetic Products Differentially Expressed In Tumors And The Use Thereof
AssigneeGanymed Pharmaceuticals AG
InventorsUgur Sahin, Özlem Türeci, Michael Koslowski
Life of this patent
Estimating the term…
Abstract
The present technology relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the present technology also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.
Claims15
A method of treating cancer comprising
- administering to a patient having said cancer a purified antibody or an antigen binding fragment thereof that specifically binds to a deglycosylated epitope of a tumor-associated antigen that is expressed or abnormally expressed on a cell, said tumor-associated antigen being selected from the group consisting of:
- (a) a tumor-associated antigen comprising the amino acid sequence of SEQ ID NO:
- 16;
- and (b) a tumor-associated antigen encoded by a nucleic acid comprising SEQ ID NO:
- 7, wherein said cancer is selected from the group consisting of lung cancer, pancreatic cancer, esophageal cancer, stomach cancer, gastric carcinoma, liver cancer, ear nose throat (ENT) cancer.
2 more elements
Dependencies are inferred from the claim text.